Sarepta Therapeutics Inc (SRPT) Stock Analysis
Verdict: HOLD
Successive triple-digit earnings beats are hitting a wall of technical weakness and insider apathy, creating a value trap or entry window.
Investment score: 62/100
Analysis as of
Is Sarepta Therapeutics Inc stock worth reviewing? The TradeMates thesis
The model sees a fundamentally improving company with severe technical momentum issues. While earnings quality is high, the stock's failure to rally on huge beats is a warning sign.
7-factor investment score
- Valuation: 70/100 (weight 20%)
- Financial Health: 55/100 (weight 15%)
- Technical Momentum: 40/100 (weight 15%)
- Earnings Quality: 85/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 65/100 (weight 10%)
- Risk-Adjusted Return: 60/100 (weight 15%)
Sarepta Therapeutics Inc opportunities and risks
What speaks for SRPT
- Earnings Momentum Outperformance
What speaks against SRPT
- Technical capitulation and lack of buyer interest
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| SRPT | n/a | 0.9x | n/a | 45.8% | -6.9% | 4.4% |
| GENB | n/a | 58.2x | n/a | 100.0% | -637.0% | -11.0% |
| SNDX | n/a | 7.0x | n/a | 97.5% | -87.6% | -12.5% |
| BCAX | n/a | 0.0x | n/a | 0.0% | 0.0% | -8.2% |
| RXRX | n/a | 30.3x | n/a | -46.7% | -945.9% | -21.2% |
| TRAX | n/a | 0.0x | n/a | 0.0% | 0.0% | -4.7% |
| Peer median | n/a | 7.0x | n/a | 0.0% | -87.6% | -11.0% |
Frequently asked questions about Sarepta Therapeutics Inc (SRPT)
Is SRPT stock a good investment?
The TradeMates model rates Sarepta Therapeutics Inc as HOLD with an investment score of 62/100. The model sees a fundamentally improving company with severe technical momentum issues. While earnings quality is high, the stock's failure to rally on huge beats is a warning sign. This is algorithmic model output, not personal investment advice.
Is SRPT stock a buy?
The TradeMates model verdict for SRPT is HOLD with an investment score of 62/100. Treat this as a model signal to review, not a personal buy recommendation.